The ABSCF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABSCF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ABSCF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ABSCF Detailed Price Forecast - CNN Money||View ABSCF Detailed Summary - Google Finance|
|View ABSCF Detailed Summary - Yahoo! Finance||View ABSCF Stock Research & Analysis - Zacks.com|
|View ABSCF Trends & Analysis - Trade-Ideas||View ABSCF Major Holders - Barrons|
|View ABSCF Call Transcripts - NASDAQ||View ABSCF Breaking News & Analysis - Seeking Alpha|
|View ABSCF Annual Report - CompanySpotlight.com||View ABSCF OTC Short Report - OTCShortReport.com|
|View ABSCF Fundamentals - TradeKing||View ABSCF SEC Filings - Bar Chart|
|View Historical Prices for ABSCF - The WSJ||View Performance/Total Return for ABSCF - Morningstar|
|View the Analyst Estimates for ABSCF - MarketWatch||View the Earnings History for ABSCF - CNBC|
|View the ABSCF Earnings - StockMarketWatch||View ABSCF Buy or Sell Recommendations - MacroAxis|
|View the ABSCF Bullish Patterns - American Bulls||View ABSCF Short Pain Metrics - ShortPainBot.com|
|View ABSCF Stock Mentions - StockTwits||View ABSCF Stock Mentions - PennyStockTweets|
|View ABSCF Stock Mentions - Twitter||View ABSCF Investment Forum News - Investor Hub|
|View ABSCF Stock Mentions - Yahoo! Message Board||View ABSCF Stock Mentions - Seeking Alpha|
|View Insider Transactions for ABSCF - SECform4.com||View Insider Transactions for ABSCF - Insider Cow|
|View ABSCF Major Holdings Summary - CNBC||View Insider Disclosure for ABSCF - OTC Markets|
|View Insider Transactions for ABSCF - Yahoo! Finance||View Institutional Holdings for ABSCF - NASDAQ|
|View ABSCF Stock Insight & Charts - FinViz.com||View ABSCF Investment Charts - StockCharts.com|
|View ABSCF Stock Overview & Charts - BarChart||View ABSCF User Generated Charts - Trading View|
AB Science situation and future prospects presented during the Combined General Shareholders' Meeting held on July 29 2018
Posted on Tuesday July 03, 2018
A Combined General Shareholders` Meeting was held on July 29, 2018 in Paris. The shareholders present or represented together held 18,861,180 shares, representing respectively 45.39% of the total number of shares and 60.75% of the voting rights. All resolutions submitted to the vote of the shareholders have been adopted, with the exception of the 24th resolution, which was rejected.
AB Science reports positive IDMC recommendation based on an interim analysis of the masitinib phase 3 study in prostate cancer
Posted on Tuesday June 19, 2018
FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the positive recommendation of the Independent Data Monitoring Committee (IDMC), following the interim analysis of study AB12003 in the first-line treatment of metastatic castrate resistant prostate cancer (mCRPC). Study AB12003 is an international, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study in first-line metastatic castrate resistant prostate cancer (mCRPC).
FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces its decision not to pursue the re-examination procedure that the company initially requested for the marketing authorization application of masitinib in the treatment of amyotrophic lateral sclerosis (ALS). AB Science determined that the re-examination procedure would not be the most appropriate format to address all the pending concerns raised by the Committee for Human Medicinal Products (CHMP).
AB Science SA. (EPA:AB): Earnings Growth Remains Elusive
Posted on Wednesday May 09, 2018
In December 2017, AB Science SA. (ENXTPA:AB) released its latest earnings announcement, which indicated company earnings became less negative compared to the previous year’s level – great news for investorsRead More...